Translation. Region: Russian Federation –
Source: Novosibirsk State University –
An important disclaimer is at the bottom of this article.
A second-year master's student at the Department of Biomedical Physics is conducting a study on boron accumulation in tumor cells after the administration of boron preparations as potential delivery vehicles for boron neutron capture therapy (BNCT). Faculty of Physics of Novosibirsk State University Ksenia Kuzmina is working on this study as part of a large research team that includes Novosibirsk State University, the Budker Institute of Nuclear Physics SB RAS, the Lebedev Physical Institute RAS, the Prokhorov General Physics Institute RAS, and the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS. Her supervisor is Anna Kasatova, a senior researcher at the INP SB RAS and a PhD candidate in medicine. The work is being carried out as part of the strategic technology project "Center for the Integration of Personalized Biomedicine, Pharmacy, and Synchrotron and Binary Technologies" of the Priority 2030 program.
Boron neutron capture therapy (BNCT) is a binary form of radiation therapy based on the selective destruction of malignant tumor cells. The key principle of this therapy is the selective destruction of only those cells that contain sufficient amounts of the isotope boron-10. Targeted boron delivery agents are essential for successful implementation of BNCT. Conducting studies on the accumulation of boron-containing agents is an important step in BNCT planning.
This therapy method works by injecting a boron-containing drug into the patient's body, which accumulates specifically in cancer cells. The patient is then irradiated at the INP SB RAS using the VITA (Vacuum Insulated Tandem Accelerator) neutron source. Neutrons interact with the boron accumulated in the tumor, triggering a nuclear reaction that produces heavy ions and alpha particles. These particles destroy the tumor during the nuclear reaction but spare healthy cells, which do not accumulate sufficient boron. Currently, boron-phenylalanine, a second-generation drug for this purpose, is primarily used in clinical practice for targeted boron delivery. Despite promising results obtained in clinical trials, the limited ratio of boron in the tumor to normal tissue in patients treated with boron-phenylalanine requires the development of more effective and selective boron delivery systems. Our Moscow physicist and chemist colleagues synthesized elemental boron nanoparticles, functionalized them with a biocompatible Silane-PEG coating to improve their pharmacokinetic properties, and sent them to us for study of the suitability of this drug for BNCT as a potential agent for boron delivery to tumors, said Ksenia Kuzmina.
Studies of the biodistribution and cytotoxicity of boron nanoparticles were conducted both in vitro (on living cell cultures) and in vivo (on laboratory mice). Two human tumor cell lines—breast carcinoma (BT474) and glioblastoma (U87)—were used in the in vitro study, as well as healthy cells—human fibroblasts (BJ-5ta). The studies established that these nanoparticles were nontoxic for all three cell lines at the concentrations required for successful BNCT. The greatest BNCT effect was observed for the BT474 cell line; according to clonogenic analysis, the proportion of surviving cells was less than 1%. The proportion of surviving U87 cells in the BNCT group was 35%, which significantly differs from the result obtained in the control group.
To study the in vivo biodistribution of boron after intratumoral administration of elemental boron nanoparticles to mice bearing the BT474 tumor, the scientists used inductively coupled plasma atomic emission spectrometry. The boron concentration in the tumor was 163 μg/g 30 minutes after administration, and 64 μg/g after 90 minutes. Boron-10 concentrations in the blood and muscle were significantly lower. The tumor-to-normal tissue ratio of boron concentrations was 15 and 4 at the 30- and 90-minute time points, respectively, exceeding the ratio for second-generation targeted delivery agents. This indicates the greater selectivity of the nanoparticles studied.
"Research into the accumulation of boron nanoparticles in tumor and healthy cells is ongoing. Our goal is to find a delivery system that will accumulate very well in tumors but retain minimally in the blood, kidneys, liver, and brain. With the launch of the Siberian Ring Photon Source (SKIF), we will be able to screen new compounds for the development of targeted boron delivery systems, study the mechanism of this process, and determine the molecular structures of these substances. We hope to be among the first users of SKIF," said Ksenia Kuzmina.
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.
